Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
National Institute of Allergy and Infectious Diseases (NIAID) · NIH Institute/Center · RFA-AI-27-018
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $7M total
- DeadlineFinal application due date.
- Jun 20, 2029
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- R61
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 10
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- One-time
- Open dateWhen applications open (or opened).
- Oct 6, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $7M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Optional / allowed
Research areas
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
The purpose of this notice of funding opportunity (NOFO) is to support implementation research on strategies to improve the uptake, implementation, sustainment, scale and/or spread of evidence-based prevention, treatment, and care interventions in communities in the U.S. significantly impacted by HIV. Projects should be large in scale with high potential for research and public health impact. Specifically, large single site studies, multi-site studies, and comparative studies are encouraged as scientifically appropriate.